Pate, Alexander http://orcid.org/0000-0002-0849-3458
Barrowman, Michael
Webb, David
Pimenta, Jeanne M
Davis, Kourtney J
Williams, Rachael
Van Staa, Tjeerd
Sperrin, Matthew http://orcid.org/0000-0002-5351-9960
Clinical trials referenced in this document:
Documents that mention this clinical trial
P26 How does the salford lung study in copd (sls copd) patient population fit into the gold 2017 classification grid?
https://doi.org/10.1136/thoraxjnl-2017-210983.168
Pragmatic randomised controlled trials in COPD and asthma: how to guide clinical practice
https://doi.org/10.1136/bmjresp-2022-001303
P270 Identification of responder groups to fluticasone furoate/vilanterol (ff/vi) in the salford lung study in copd (sls copd) using a cluster analysis model
https://doi.org/10.1136/thoraxjnl-2017-210983.412
P27 Deprivation in the copd salford lung study (sls) is associated with higher healthcare costs but does not moderate the main outcomes
https://doi.org/10.1136/thoraxjnl-2017-210983.169
P269 Describing adherence data in a clinical effectiveness trial: the salford lung study in copd (sls copd)
https://doi.org/10.1136/thoraxjnl-2017-210983.411
Study investigating the generalisability of a COPD trial based in primary care (Salford Lung Study) and the presence of a Hawthorne effect
https://doi.org/10.1136/bmjresp-2018-000339
Funding for this research was provided by:
GlaxoSmithKline (PRJ2282/201491)